TNI BioTech, a biotech company focused on combating fatal diseases through the activation and mobilization of the body's immune system, announced that effective immediately Dr. Ronald Herberman has joined the management team as Senior Vice President of Research and Development and Chief Medical Officer. Dr. Herberman's will be responsible for leading the company's global development, clinical research, and medical initiatives.
Dr. Herberman brings extensive experience in all phases of drug development and drug portfolio management - including acquisition of new assets, and in dealing with regulators and government agencies. Previously, he held the position of Chief Medical Officer at Intrexon Corporation where he was responsible for scientists and clinicians in discovery, clinical research and development, regulatory affairs, and medical affairs. He was also the founding director of the University of Pittsburgh Cancer Institute and Associate Vice Chancellor for Cancer Research, Hillman Professor of Oncology, and Professor of Medicine at the University of Pittsburgh School of Medicine.
An internationally recognized tumor immunologist, Dr. Herberman has made major discoveries in his field and has fostered the application of this information to novel approaches to cancer therapy, diagnosis, and prevention. Dr. Herberman has received numerous awards, including the Lifetime Science Award from the Institute for Advanced Studies in Immunology and Aging. The significance of Dr. Herberman's foundational scientific discoveries is accentuated by his recognition as one of the 100 most-cited research authors during the 1980s.
Dr. Nicholas Plotnikoff, TNI BioTech, Inc. Chairman, stated, "In order to successfully become a world-class leader, we need significant expertise in clinical, regulatory and leadership development, along with a deep knowledge of immunology and Dr. Herberman brings demonstrated strengths in these areas having made major discoveries in his field and has fostered the application of this information to novel approaches to cancer therapy, diagnosis and prevention during his time as a leader at the National Cancer Institute and Founding Director of the University of Pittsburgh Cancer Institute."
"During his career, Dr. Herberman has been recognized as a leader in the field of immunology," Dr. Plotnikoff continued. "The phenomenon of natural killer (NASDAQ:NK) cell-mediated cytotoxicity against tumors was first discovered in Dr. Herberman's laboratory at the National Cancer Institute in the early 1970s. In addition to his pioneering investigation of NK cells, Dr. Herberman has played a leading role in multiple areas of tumor immunology. TNI BioTech therapies and treatments draw upon the theory that medicine can enlist the body's own immune system to combat cancer and autoimmune diseases that are Dr. Herberman's specialty. His experience and strategic perspective precisely meet TNI BioTech's needs today."
Dr. Herberman commented, "I am very excited to assume a leadership position in TNI Biotech Inc. I have had the privilege to know Dr. Plotnikoff for about 30 Years and I have been very impressed with his pioneering studies of the effects of opioid peptides on the immune system. I am convinced that TNI Biotech's drugs have much potential for the treatment of not only cancer, but also a range of other diseases including multiple sclerosis, HIV/AIDS, and Crohn's Disease. I intend to rapidly build on a pre-existing foundation of clinical research with low dose naltrexone and met-enkephalin, and develop innovative approaches to use them to stimulate the immune system to make an impact on these and other chronic diseases."
To learn more about the company and its immunotherapy technologies, visit tnibiotech.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net